Induced pluripotent stem cells, a giant leap for mankind therapeutic applications

José Bragança, João André Lopes, Leonardo Mendes-Silva, João Miguel Almeida Santos

Abstract

Induced pluripotent stem cells (iPSC) technology has propelled the field of stem cells biology, providing new cells to explore the molecular mechanisms of pluripotency, cancer biology and aging. A major advantage of human iPSC, compared to the pluripotent embryonic stem cells, is that they can be generated from virtually any embryonic or adult somatic cell type without destruction of human blastocysts. In addition, iPSC can be generated from somatic cells harvested from normal individuals or patients, and used as a cellular tool to unravel mechanisms of human development and to model diseases in a manner not possible before. Besides these fundamental aspects of human biology and physiology that are revealed using iPSC or iPSC-derived cells, these cells hold an immense potential for cell-based therapies, and for the discovery of new or personalized pharmacological treatments for many disorders. Here, we review some of the current challenges and concerns about iPSC technology. We introduce the potential held by iPSC for research and development of novel health-related applications. We briefly present the efforts made by the scientific and clinical communities to create the necessary guidelines and regulations to achieve the highest quality standards in the procedures for iPSC generation, characterization and long-term preservation. Finally, we present some of the audacious and pioneer clinical trials in progress with iPSC-derived cells.

Key words: Induced pluripotent stem cells; Reprogramming; Cell-based therapy; Stem cell banking; Disease modelling
In this review, we present the current status on the basic and applied research involving induced pluripotent stem cells (iPSC). We discuss concerns around iPSC reprogramming technology, and present initiatives that have been recently developed for the use of iPSC in health-related issues. We also introduce some of the audacious clinical trials already ongoing to treat patients with cells derived from iPSC.

Citation: Bragança J, Lopes JA, Mendes-Silva L, Almeida Santos JM. Induced pluripotent stem cells, a giant leap for mankind therapeutic applications. World J Stem Cells 2019; 11(7): 421-430
URL: https://www.wjgnet.com/1948-0210/full/v11/i7/421.htm
DOI: https://dx.doi.org/10.4252/wjsc.v11.i7.421

INTRODUCTION

In 2006, Kazutoshi Takahashi and Shinya Yamanaka reported for the first time the reprogramming of induced pluripotent stem cells (iPSC) from mouse somatic cells by forced expression of the transcription factors Oct4, Sox2, Klf4 and c-Myc, now termed Yamanaka factors[1]. Subsequently, the Yamanaka factors, or other combinations of factors were successfully used to reprogram a wide range of mouse or human somatic cells into iPSC[2-5]. iPSC achieve a high degree of dedifferentiation and acquire properties similar to those of embryonic stem cells (ESC). Indeed, iPSC and ESC are morphologically indistinguishable, and in vitro these cells have the potential to differentiate into cells of the three germ layers (ectoderm, endoderm and mesoderm) and to originate virtually all cells of adult organisms. Like mouse ESC, mouse iPSC have the capacity to aggregate and integrate the inner cell mass, and participate in the development of an embryo upon injection into a host blastocyst and its subsequent transfer into a foster pseudo pregnant female. Additionally, iPSC which contribute to the germline have the potential to generate viable and fertile animals[6-9].

This novel reprogramming strategy applicable to human cells raised a great interest in the scientific and medical community, as iPSC represent an alternative source of pluripotent cells to human ESC. Moreover, iPSC present the advantage of being derived from somatic cells collected in a non-invasive manner, harbouring the individual’s genetic background, thus being autologous and limiting immune rejections[10]. iPSC also overcome ethical concerns associated to the derivation of human ESC from blastocysts. At present, advancements and refinements have been made to the original reprogramming procedure to circumvent some critical experimental issues, such as the delivery of the reprogramming factors with integrative vectors. Although Yamanaka factors are commonly used for reprogramming iPSC, other transcription factors, epigenetic regulators, microRNAs and/or small molecules have been shown to cooperate or substitute Yamanaka factors for the process. Reprogrammed cells are currently an invaluable tool for in vitro disease modelling, high-throughput screens for drug discovery and toxicity tests. In addition, reprogramming raises the possibility for the derivation of patient-specific autologous cells for personalized therapies[11]. Here, we introduce some of the challenges remaining to be faced to originate iPSC in a reliable fashion and with the quality required for safe clinical applications. We also present the current and future applications and therapeutic strategies involving iPSC to improve health.

CHALLENGES TO OVERCOME

The constant visitation to the initial reprogramming strategy by many researchers worldwide has led to the understanding of the molecular bases and to the improvement of the cell reprogramming process, bringing iPSC closer to safe clinical applications. However, the full translational potential of iPSC is still hampered by flaws, such as the inefficiency and the frequent incomplete reprogramming of the cells, and de novo mutations occurring during the reprogramming process and during the cultivation of generated iPSC[12,13]. The efficiency to reprogram somatic cells into iPSC remains low (often much less than 1%), and likely further decline in aged cells or in cells with a high number of divisions, and by the action of the reprogramming factors themselves which trigger a senescence-like response[13-15]. Intriguingly, paracrine factors secreted by senescent cells have been reported to facilitate the
reprogramming of non-senescent cells by Yamanaka’s factors, in vivo in mouse tissues\cite{33}. In any case, the reprogramming of aged-cells and senescent cells has been successfully achieved and gave rise to rejuvenated iPSC with properties similar to those originated from young somatic cells\cite{34-36}.

Exhaustive studies of many iPSC worldwide have invariably indicated the existence of disparities in gene expression between iPSC and ESC, some of which may be attributed to genetic and epigenetic background variations already present in the somatic cells and ESC. However, the full impact of the minute number of differentially expressed genes in iPSC properties and specification during differentiation remains unknown. A variability in X chromosome inactivation and reactivation of human female iPSC has also been observed\cite{21,22-27}. Indeed, some human iPSC maintained the inactivation of the X chromosome during the reprogramming process, while others displayed both X chromosomes reactivated or with abnormal/partial reactivation. The stability of the X chromosome reactivation/inactivation may also vary with the cultivation of the cells overtime, the freezing and thawing processes required for the long-term conservation of these cells. This may result in a mixed population of iPSC displaying discrepant biological properties due to variable states of X chromosomes activation and inactivation. In addition, the inactivation of X chromosomes may occur randomly during differentiation\cite{21}. These points are of particular interest if iPSC are to be used to model early human embryonic development, X-linked diseases that depend on the activation of one or both X chromosomes and inherited sex-modulated disorders, such as autism\cite{28-30}. Moreover, teratoma formation assays, performed routinely to determine the pluripotency of iPSC, do not discriminate between chromosome X activation/inactivation status, and other specific tests have to be performed to determine X chromosome status\cite{31,32,33}.

De novo point mutations and genetic variations occurring during the initial steps of the reprogramming process have been reported by several research groups\cite{24-28}. The mutations may not only occur in open chromatin regions including protein coding regions and transcriptional regulatory elements, but also in non-coding regions such as lamina-associated heterochromatin due to oxidative stress aggressions\cite{29}. Chromosomal aberrations, such as abnormal chromosome number have also been described in iPSC and ESC\cite{30}. Fibroblasts are commonly the favourite primary cell source for reprogramming, but these cells are very resistant to genomic alterations. Thus, cells less tolerant for the accumulation of mutations and genomic aberrations should be identified and preferably utilized for reprogramming. Mutations also accumulate in mitochondrial DNA of somatic cells with age, and are likely to limit the metabolic function and affect the energy supply in iPSC-derived differentiated cells, thus affecting their potential for disease modelling, drugs screens and therapeutic applications\cite{31,32,33}.

Another foreseen advantage of iPSC is the capacity to generate them for autologous purposes (Figure 1), in order to produce cells tolerated by the host organism. However, this high expectation of immune tolerance was questioned by the elimination of mouse iPSC transplanted in isogenic mice\cite{34}. The immune responses were attributed to partial reprogramming and genomic instability of the iPSC, and the transplantation of terminally differentiated cells did not show immunogenicity\cite{35}. This observation suggests that differentiated cells from iPSC, which are the cells envisioned to be used in therapeutic approaches, would not trigger aggressive immune response in patients. Nevertheless, the immunotolerance of cells prepared autologously from iPSC has to be assessed and controlled for safe clinical applications, which may still require a preventive immunosuppression of the patients. Thus, for the safe use of iPSC in clinical, and even to model diseases faithfully, it is important to further understand the genetic and epigenetic mechanisms underlying the reprogramming process and obtain protocols to generate iPSC with the highest quality, and purity, and test their integrity and functionality.

**PROMISING NON-THERAPEUTIC APPLICATIONS FOR iPSC**

iPSC technology allows the reprogramming of cells from individuals in the context of their genetic background, and the genetic and epigenetic behaviours of iPSC have been showed to reflect those of the proper cells of a donor individual\cite{34,36}. Therefore, iPSC are considered a great tool to model human diseases, and if reprogrammed from cells of a patient with genetic variations causing the disease, iPSC have the potential to generate cells or tissue-like structures in vitro mimicking those of the patient affected by the disease of interest (Figure 1). However, inter and intra-clonal (epi) genetic variability of iPSC acquired during reprogramming and or the differentiation
Applications of human induced pluripotent stem cells. A: Pharmacotherapy can be optimized to the patients by testing the drugs on cells differentiated from patient-derived induced pluripotent stem cells (iPSC) to model the disease (blue panel). This approach may be used to determine the adequate treatment plan to specific patients and to limit side effects or non-responsiveness experienced by conventional clinical approaches supported by medical history and examinations, and test results to implement the treatment based on generic clinical approaches; B: iPSC-derived from patients may also be corrected for genetic defects and consequently used to treat the patients in cell-based or regenerative therapies (orange panel); C: iPSC may be used to derive immune cells to eliminate cancer cells, or to be inactivated and injected to vaccinate people against cancer cells; D: iPSC used to study developmental processes, model diseases and test drugs to assess toxicity in specific cell types (yellow panel); E: iPSC originated from non-diseased individuals are being characterized and preserved in Biobanks worldwide for allogenic cell-based therapies in HLA matched patients (green panel). iPSC: Induced pluripotent stem cells.

The correct differentiation of iPSC into the target cells relevant to model the disease of interest is also critical, and is often hampered by the limited knowledge about the experimental conditions leading to the proper cell differentiation and the variability existing in the differentiation processes. The major challenge for disease modelling using iPSC remains to establish the right cell type(s) with a phenotype which represent accurately the pathological aspects of the disease of interest. Another interesting feature is that iPSC are pluripotent and their differentiation can be triggered in order to mimic early steps of embryonic development, which make them a cell source of choice to study congenital or early age onset diseases. Many groups have already used iPSC to model the pathophysiology of a variety of diseases, such as cardiovascular diseases, neuronal and neurological disorders, and cancer amongst others. However, for diseases which are multigenic and/or age-dependent with late onset, or complex and systemic, iPSC may be more difficult to use for establishing a disease model. Organoids, which are 3-dimensional cellular structures mimicking the organization and functions of organs or tissues, may also be generated by differentiation of iPSC to obtain more complex cellular models in vitro. In addition, iPSC are also an invaluable tool to study the genetic pathways involved in diseases in well-controlled environments, and to test the effect of novel and known drugs in patient-derived iPSC.

Interestingly, primary cancer cells from different types of human cancers, such as melanoma, gastric cancer, glioblastoma and pancreatic ductal adenocarcinoma,
Among others, have been successfully reprogrammed into iPSC or at least into pluripotent cells, offering new possibilities to study early stages of cancer initiation and progression in vitro\textsuperscript{[18,39]}. iPSC might be especially useful to model cancers emerging at young ages or with familial inherited characteristics, since these cancers have an early onset which may be promoted by the embryonic developmental process itself, which is recapitulated to a large extent during iPSC differentiation. An obvious limitation to this model is that it fails to be submitted to environmental factors such as chemical pollution, smoking and virus infection, among others, that may contribute to tumorigenesis. Another limitation comes from the fact that iPSC reprogramming process changes the epigenetic status of the original source cell, which in the case of cancer cells may also contribute to their tumorigenic nature.

iPSC can also be used for toxicity tests and drug discovery screening studies to treat diseases in a more personalized manner\textsuperscript{[40-42]}. Indeed, numerous studies have indicated that iPSC recapitulate in vivo the response of the cell-donor individuals to drug exposition in vitro. This observation implies the possibility to perform highly accurate and personalized preclinical trials in vitro using iPSC or iPSC-derived cells (Figure 1). Since pre-clinical phase trials are critical to decide about the progression of drug development for clinical applications, thorough experiments and control methods have yet to be implemented and standardized to test new drugs\textsuperscript{[43]}. In 2011, the US Food and Drug Administration/FDA has established a set of guidelines to manufacture and evaluate the quality of cells and tissues derived from stem cells for patients’ regenerative medicine applications, but do not make recommendations for the use of cells for in vitro assays. The International Society for Stem Cell Research/ISSCR has also released recommendations to guide physicians, ethical committees and review boards to evaluate early-phase stem cells based clinical trials (“Stem Cell-Based Clinical Trials: Practical Advice for Physicians and Ethics/Institutional Review Boards”, http://www.isscr.org/docs/default-source/clinical-resources/isscr-stem-cell-based-clinical-trials-practical-advice_final_23jan2018.pdf?sfvrsn=2). However, these efforts to prepare guidelines and recommendations to set gold standards and to evaluate the quality of products derived from iPSC, or stem cells in general, for in vitro (pre) clinical assays and drug toxicity testing have to be continued to reach a safe and reliable use of stem cells.

**REPROGRAMMING CELLS FOR ANTI-AGING AND CANCER TREATMENT**

An interesting concept of cell-aging reversion in vivo, which has allowed to prolong the lifespan of a mouse model of premature aging, has also emerged with the reprogramming technology\textsuperscript{[43]}. Indeed, the short-term exposure to Yamanaka factors has contributed to a partial reprogramming of cells, and amended the physiological and cellular hallmarks of aging, due to a probable remodelling of the epigenetic marks which are acquired during aging\textsuperscript{[44]}. Further understanding of the partial reprogramming timings and markers may harness balanced conditions to obtain rejuvenated cells with a full potential to perform their functions and with a minimal dedifferentiation state to avoid oncogenic risks\textsuperscript{[45]}. Partial reprogramming approaches and the consequent epigenetic rejuvenation may serve to develop future interventions for the treatment of age-related diseases, improvement of health and longevity\textsuperscript{[42,43]}. Further understanding of the partial reprogramming technology may serve to develop future interventions for the treatment of age-related diseases, improvement of health and longevity\textsuperscript{[42,43]}. Indeed, iPSC were used to derive human dendritic cells and macrophages which have a potent antigen presenting activity with the capacity to activate T-cells, thus presenting a great potential to be used for cancer immunotherapies. Indeed, iPSC reprogrammed from T-cells (isolated from peripheral blood mononuclear cells) have been shown to retain the expression of the original T-cell receptor/TCR rearrangement\textsuperscript{[46]}. Thus, these cells could be a source for illimited production of specific clones of T-cells, bypassing their residence in the thymus for their development and maturation. Human tumour antigen-specific cytotoxic T-cells have also been generated by several groups, and iPSC can also be engineered to harbour chimeric antigen receptors/CAR targeting cancer cells\textsuperscript{[47]}. Natural Killer cells harbouring CAR constructs targeting tumours have also been generated from iPSC, and showed to inhibit the growth of tumours in vivo\textsuperscript{[48]}. These approaches may serve to develop effective treatments for refractory oncologic malignancies. Furthermore, a recent report has showed that iPSC may express tumour-associated antigens and be used for autologous tumour vaccination\textsuperscript{[49]}. Indeed, the injection of irradiated mouse iPSC and adjuvant CpG (successfully used in tumour vaccination) in mouse, triggered a strong in vivo immune response which controlled the tumour growth from breast cancer, melanoma and mesothelioma.
injected cells. Thus, the injection of irradiated-iPSC led to the instatement of a broad anti-tumoral immune status able to restrain the development of multiple cancers without any overt adverse effect\(^4\), suggesting that this approach has the potential to be translated in clinical applications.

**ONGOING CLINICAL TRIALS**

Many promising therapeutic applications are currently being tested in preclinical experiments using iPSC-derived cells for their potential to generate functional cells able to replace damaged or dysfunctional tissues in patients\(^5\). However, the era of human clinical trials using iPSC-derived cells has already started. Indeed, the first reported clinical trial involving iPSC-derived cells was designed to treat the Age-Related Macular Degeneration (AMD), a disease that affects the macula of the eye and results in the blur of the central vision\(^6\). In 2013, sheets of retinal pigment epithelial (RPE) cells, differentiated from patient-derived iPSC, were transplanted into the eyes of a patient suffering AMD. Six months after transplantation, the patient visual treatment acuity was improved with no safety-related concerns. However, as the second trial participant was ready to start, two mutations, that were not present in the original reprogrammed fibroblasts, were detected in the RPE cells used to treat the first patient. While further analysis revealed that the risk of carcinogenesis was low, the study was halted and only resumed in 2016. The first formal trial using iPSC was approved in 2016 when Cynata Therapeutics launched the first clinical trial using an allogeneic iPSC-derived mesenchymal stem cell called CYP-001\(^6\). Cynata Therapeutics just recently concluded the Phase 1 clinical trial of CYP-001 for the treatment of steroid-resistant acute graft versus host disease/GvHD, and the results showed positive safety and efficacy data for the treatment of the disease. Cynata Therapeutics is currently planning a phase 2 trial. In 2018, the Kyoto University announced the first clinical trial to treat Parkinson’s disease using iPSC-derived dopaminergic progenitors to be transplanted into human patients. The objective of this trial will be to evaluate the safety and efficacy of the transplantation of iPSC-derived dopaminergic neurons into the brain of Parkinson’s disease patients\(^5\). In the oncological front, the American Company Fate Therapeutics has recently approved the usage of a NK cell-based cancer immunotherapy for the treatment of advanced solid tumours with cells derived from a clonal master characterized iPSC line\(^5\). This study is expected to evaluate the safety and tolerability of multiple doses of these cells in subjects who have progressed or failed with immune checkpoint inhibitors therapy. Recently, a clinical trial has been approved to generate sheets of cardiomyocytes that surgeons plan to implant into the heart of three patients with heart diseases\(^5\). While some companies and researchers are patiently waiting for the results of clinical trials concerning the iPSC regenerative potential, others are currently looking into other therapeutic strategies. For instance, with CRISPR-Cas9 technologies, stem cell biologists are attempting to repair mutated genes in human iPSC before using iPSC-derived cells to treat the patients.

**iPSC BANKING**

The use of iPSC for autologous therapeutic purposes seems more appropriate, since the cells derived from the patient should present a reduced risk of immune rejection\(^6\). However, in light of recent findings, an autoimmune reaction to iPSC-derived cells may not be completely avoided\(^6\). In addition, the use of iPSC from patients for autologous purposes may, in many cases, require the correction of genetic defects that contribute to the pathology (Figure 1). On the other hand, having allogenic iPSC already generated, characterized and tested for the absence of contaminating agents and for the integrity of the (epi)genome would save time in the preparation of iPSC-derived cells needed for engraftment and treatment of patients. In this case, the human leucocyte antigens/HLA of iPSC should be typed in order to be able to quickly match the cells with the patients in need\(^6,7\). In principle, this strategy would reduce the costs and the number of “off-the-shelf” iPSC samples that could be stored in biobanks. Indeed, a few hundreds of homozygous iPSC lines could provide a match for more than 90% of genetically homologous populations\(^6,7\). However, banking the total number of iPSC necessary to match all haplotypes of multi-ethnic populations with genetic heterogeneity, such as the population of North America, may be much more challenging and costly\(^4\). Nevertheless, a number of banking initiatives, both to store iPSC for research and clinical purposes, are in progress in Europe, Asia and North America, with coordinated standards to have a
well-documented, traceable and quality controlled repository of iPSC. However, the banking initiatives do not reach a consensus in the general public and scientists, since there are only a few clinical trials ongoing with results that remain to prove that iPSC-derived cells are useful for successful therapies. In addition, there is a debate on which financial entities (private or public) should support the high costs of these initiatives. It is also important to set high standard regulation and quality control for iPSC production, characterization and cell preservation, as well as their use in clinical environments. Finally, it is also utterly important to provide the general public, and patients in particular, all the necessary information about the procedures and the risks associated to the use of iPSC-derived cells, the limitations of these novel approaches, and to be realistic with the expectations of the patients.

CONCLUSION

The ability to generate pluripotent stem cells, iPSC, from human somatic cells using a simple experimental approach easy to implement, has undeniably opened new possibilities for modelling diseases and to undertake developmental studies that could never have been performed before (Table 1). The bulk of the molecular mechanisms involved in the reprogramming process has been largely unveiled, which has already allowed great improvements in the iPSC generation process. Consequently, iPSC have achieved a quality sufficient to be used in novel clinical approaches. The use of patient-derived iPSC offers the possibility to develop and test patient-specific pharmacotherapies and derive stem cells which may be corrected for genetic defects before their use for autologous purposes (Figure 1). In the field of cancer, the study of iPSC biology and their reprogramming mechanism has not only provided new insights in epigenetic changes contributing to cancer, but has positioned iPSC as a cell source to originate immune cells with great potential for the development of immunotherapies against cancer. The inactivated iPSC themselves are now thought to be instrumental for future vaccinations and to provide protection against cancers.

Even studies of incomplete reprogramming processes of iPSC have provided new means to revert aging in cells and paved the way for future research directions aiming to treat age-related diseases and to improve health in longevity. In prevision of their future potential use in therapies, stem cells and iPSC research communities are coming together to set up guidelines and recommendations to delineate the best approaches and practices to obtain and characterize iPSC with the highest quality necessary to derive cells for clinical applications. Efforts are also made worldwide to organize biobanks with traceable information and quality to store iPSC, that would be ready for prompt clinical interventions. There is no doubt that iPSC technology has helped basic and clinical researchers to make a leap forward in many fields of basic and applied research, including cell-based therapies. This relatively recent and evolving technology has rapidly opened a conduit between the bench and the bedside, and is already the object of several pioneering clinical trials to treat various diseases, including neurodegenerative diseases. Although these clinical assays may seem premature to many scientists and clinicians, their results are awaited with high expectations and will be determinant to accelerate and diversify clinical interventions based on iPSC-derived cells.

Although many technical hurdles remain to be surpassed for iPSC technology to fully reach its potential. In just over ten years after its first development this technology has remarkably led to several clinical applications, and provide new ways of obtaining disease models in vitro to better study the mechanism of human pathologies and to improve patients' treatment in a more adequate and personalized manner. Thus, iPSC technology has already been “a giant leap” in terms of obtention of human cells with incredible versatility and potential for therapeutic applications.
| Weak points | Possible solutions | Strong points | Further improvements |
|-------------|--------------------|---------------|---------------------|
| Slow, inefficient and variable reprogramming process | Banking of fully characterized iPSC | Easy reprogramming process to implement | Reduce time, and increase efficiency and consistency of reprogramming |
| Differential gene expression in comparison to ESC | Improve the reprogramming using other combinations of reprogramming factors | Strong proliferation capacity | Establish culture conditions promoting genome stability |
| Variable X inactivation status and genome instability | Test for X inactivation, sequencing to check for genome integrity | Allogenic and personalized cell therapy | Eliminate mutagenic potential and differential gene expression due to reprogramming |
| Point mutations | Whole genome sequencing to verify the absence of mutations - Possible correction by genome editing - Use cell source for reprogramming less susceptible to mutations | Model human diseases, including cancer, and test patient-specific pharmacotherapies | Establish cells (tissues) with the adequate phenotypes characterizing the disease of interest |
| Immunotolerance of iPSC-derived cells | Preventive immunosuppression | May reverse cells aging | Understanding better the molecular mechanisms of partial reprogramming and aging markers |
| Differentiation protocols must be optimized to obtain iPSC-derived cells of interest | Many protocols have already been tested and published | Originate immune cells and use iPSC as vaccines to develop immunotherapies against cancer | Increase the variety of immune cells that can be reprogrammed |
| Potential tumorigenic hazard | Use differentiated and purified cells | Pluripotent cells | Prepare functional organs |

iPSC: Induced pluripotent stem cells.

### ACKNOWLEDGEMENTS

The authors thank José António Belo (New University of Lisbon), Rui Gonçalo Martinho (University of Aveiro) and Clévio Nóbrega (University of Algarve) for insightful discussions.

### REFERENCES

1. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676 [PMID: 16904176 DOI: 10.1016/j.cell.2006.07.024]

2. Yu J, Thomson JA. Pluripotent stem cell lines. Genes Dev 2008; 22: 1987-1997 [PMID: 18676805 DOI: 10.1101/gad.169890]

3. Jaenisch R, Young R. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell 2008; 132: 567-582 [PMID: 18295570 DOI: 10.1016/j.cell.2008.01.015]

4. Lengerke C, Daley GQ. Disease models from pluripotent stem cells. Ann N Y Acad Sci 2009; 1176: 191-196 [PMID: 19796247 DOI: 10.1111/j.1749-6632.2009.04962.x]

5. Ho R, Chronis C, Plath K. Mechanistic insights into reprogramming to induced pluripotency. J Cell Physiol 2011; 226: 868-878 [PMID: 20945378 DOI: 10.1002/jcp.22450]

6. Okita K, Ichisaka T, Yamazaki S. Generation of germline-competent induced pluripotent stem cells. Nature 2007; 448: 313-317 [PMID: 17554338 DOI: 10.1038/nature05934]

7. Maherali N, Sridharan R, Xie W, Utikal J, Emini S, Arnold K, Stadtfeld M, Yachechko R, Tchieu J, Jaenisch R, Plath K, Hochedlinger K. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell 2007; 1: 55-70 [PMID: 18371336 DOI: 10.1016/j.stem.2007.05.014]

8. Wernig M, Meissner A, Foreman R, Bramblik T, Ku M, Hochedlinger K, Bernstein BE, Jaenisch R. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 2007; 448: 318-324 [PMID: 17554336 DOI: 10.1038/nature05944]

9. Blelloch R, Venere M, Yen J, Ramalho-Santos M. Generation of induced pluripotent stem cells in the absence of drug selection. Cell Stem Cell 2007; 1: 243-247 [PMID: 18371358 DOI: 10.1016/j.stem.2007.05.008]

10. Bellini M, Marchetto MC, Gage FH, Mummery CL. Induced pluripotent stem cells: the new patient? Nat Rev Mol Cell Biol 2012; 13: 713-726 [PMID: 23034453 DOI: 10.1038/nrm3448]

11. Kimbrel EA, Lanza R. Current status of pluripotent stem cells: moving the first therapies to the clinic. Nat Rev Drug Discov 2015; 14: 681-692 [PMID: 26391880 DOI: 10.1038/nrd4738]

12. Takahashi K, Yamanaka S. A decade of transcription factor-mediated reprogramming to pluripotency. Nat Rev Mol Cell Biol 2016; 17: 183-193 [PMID: 26883003 DOI: 10.1038/nrm.2016.8]

13. Lapasset L, Milhavet O, Prieur A, Bensard E, Ibbled A, Alt-Hamou N, Leschik J, Pellerost F, Ramirez JM, De Vos J, Lehmann S, Lemaître JM. Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state. Genes Dev 2011; 25: 2248-2253 [PMID: 22056670 DOI: 10.1101/gad.173922.111]
Fermini B, Coyne KP, Coyne ST. Challenges in designing and executing clinical trials in a dish studies. J Genet: R89-R98 [PMID: 29771306 DOI: 10.1093/hmg/ddy186] 2018; Hum Mol Cell Research. [PMID: 29531804 DOI: 10.1038/s41420-017-0009-2]

Challenges in designing and executing clinical trials in a dish studies. J Genet: R89-R98 [PMID: 29771306 DOI: 10.1093/hmg/ddy186] 2018; Hum Mol Cell Research. [PMID: 29531804 DOI: 10.1038/s41420-017-0009-2]
Bragança J et al. iPSC and health issues

Pharmacol Toxicol Methods 2018; 94: 73-82 [PMID: 30267757 DOI: 10.1016/vascn.2018.09.002]

Ocampo A, Reddy P, Martinez-Redondo P, Patlero-Luengo A, Hatanaka F, Hisida T, Li M, Lam D, Kurita M, Beyrat E, Arakaki T, Vazquez-Ferrer E, Donoso D, Roman JL, Xu J, Rodriguez Esteban C, Nuñez G, Nuñez Delicado E, Campistol JM, Guille J, Iripinsa Belmonte JC. In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming. Cell 2016; 167: 1719-1733.e12 [PMID: 27984723 DOI: 10.1016/j.cell.2016.11.032]

Olova N, Simpson DJ, Marioni RE, Chandra T. Partial reprogramming induces a steady decline in epigenetic age before loss of somatic identity. Aging Cell 2019; 18: e12877 [PMID: 30405724 DOI: 10.1111/acel.12877]

Zhu H, Lai YS, Li Y, Blum RH, Kaufman DS. Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy. Stem Cells 2018; 36: 134-145 [PMID: 29235195 DOI: 10.1002/stem.2754]

Brown ME, Rendon E, Rajesh D, Mack A, Lewis R, Feng X, Zhu S, Leahis RD, Niuwasyi EF. Derivation of induced pluripotent stem cells from human peripheral blood T lymphocytes. PLoS One 2010; 5: e11373 [PMID: 20617191 DOI: 10.1371/journal.pone.0011373]

Rami F, Mollanezhad H, Salehi M. Induced Pluripotent Stem Cell as a New Source for Cancer Immunotherapy. Genet Res Int 2016; 2016: 3451807 [PMID: 27019752 DOI: 10.1155/2016/3451807]

Li Y, Hermansson DL, Moriarity BS, Kaufman DS. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. Cell Stem Cell 2018; 23: 181-192.e5 [PMID: 30082067 DOI: 10.1016/j.stem2018.06.002]

Kooreman NG, Kim Y, de Almeida PE, Termglinchan V, Diecke S, Shao NY, Wei TT, Yi H, Dey D, Nelakanti R, Browner TP, Paik DT, Sagiv-Barfi I, Han A, Quax PHA, Hamming JF, Levy R, Davis MM, Wu JC. Autologous iPSC-Based Vaccines Elicit Anti-Tumor Responses In Vivo. Stem Cell 2018; 22: 501-513.e7 [PMID: 29456158 DOI: 10.1002/stem.2018.01.016]

Harding J, Mirotchnichenko O. Preclinical studies for induced pluripotent stem cell-based therapeutics. J Biol Chem 2014; 289: 4358-4393 [PMID: 24362021 DOI: 10.1074/jbc.r113.467377]

Fritsche LG, Fariss RN, Stambolian D, Abecesta GR, Curcio CA, Swaroop A. Age-related macular degeneration: genetics and biology coming together. Annu Rev Genomics Hum Genet 2014; 15: 151-171 [PMID: 24773320 DOI: 10.1146/annurev-genom-090413-025610]

Guh A, Kobold S, Sellmann S, Seiler Wulczyn AEM, Kurtz A, Löser P. Recent Trends in Research with Human Pluripotent Stem Cells: Impact of Research and Use of Cell Lines in Experimental Research and Clinical Trials. Stem Cell Reports 2018; 11: 485-496 [PMID: 30033067 DOI: 10.1016/j.stemcr.2018.06.012]

Takahashi J. Strategies for bringing stem cell-derived dopamine neurons to the clinic: The Kyoto trial. Prog Brain Res 2017; 230: 213-226 [PMID: 28552230 DOI: 10.1016/bs.prb.2016.11.004]

Sonntag KC, Song B, Lee N, Jung HL, Cha Y, Lefebre P, Neff C, Kong SW, Carter BS, Schweitzer J, Kim KS. Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects. Prog Neurobiol 2018; 168: 1-20 [PMID: 29653250 DOI: 10.1016/j.pneurobio.2018.04.005]

Stoddard-Bennett T, Reijo Pera R. Treatment of Parkinson's Disease through Personalized Medicine and Induced Pluripotent Stem Cells. Cells 2019; 8: pii: E26 [PMID: 30621042 DOI: 10.3390/cells810026]

Hu Y, Tian Z, Zhang C. Natural killer cell-based immunotherapy for cancer: Advances and prospects. Engineering 2019; 5: 106-114 [DOI: 10.1016/j.enorg.2019.01.015]

Cyranoñi D. 'Reprogrammed' stem cells approved to mend human hearts for the first time. Nature 2018; 557: 619-620 [PMID: 29844563 DOI: 10.1038/d41586-018-05278-8]

Wood KJ, Issa F, Hester J. Understanding Stem Cell Immunogenicity in Therapeutic Applications. Trends Immunol 2016; 37: 5-16 [PMID: 26687377 DOI: 10.1016/j.itol.2015.11.005]

Solomon S, Pitossi F, Rao MS. Banking on iPSC---is it doable and is it worthwhile. Stem Cell Rev 2015; 11: 1-10 [PMID: 25546140 DOI: 10.1007/s12015-014-9574-4]

Kim JH, Kurtz A, Yuan BZ, Zeng F, Lomax G, Loring JF, Crook J, Ju JH, Clarke L, Inamdar MS, Pera M, Firpo MT, Sheldon M, Rahman N, O'Shea O, Pranke P, Zhou Q, Isasi R, Rungswiswrit R, Kawamata S, Oh S, Ludwig T, Masui T, Novak TJ, Takahashi T, Fujibuchi W, Koo SK, Stacey GN. Report of the International Stem Cell Banking Initiative Workshop. Current Hurdles and Progress in Seed-Stock Banking of Human Pluripotent Stem Cells. Stem Cells Transl Med 2017; 6: 1956-1962 [PMID: 29067781 DOI: 10.1002/stem.17-0144]

Taylor CJ, Peacock S, Chaudhry AN, Bradley JA, Bolton EM. Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types. Cell Stem Cell 2012; 11: 147-152 [PMID: 22626941 DOI: 10.1016/j.stem.2012.07.014]

Nakatsuji N, Nakajima F, Tokunaga K. HLA-haplotype banking and iPS cells. Nat Biotechnol 2008; 26: 739-740 [PMID: 18612291 DOI: 10.1038/nbt0708-739]

Gourraud PA, Gilson L, Girard M, Peschanski M. The role of human leukocyte antigen matching in the development of multithetical "haplobank" of induced pluripotent stem cell lines. Stem Cells 2012; 30: 180-186 [PMID: 22045598 DOI: 10.1002/stem.772]

Andrews PW, Baker D, Benvisnity N, Miranda B, Bruce K, Brüste O, Choi M, Choi YM, Crook JM, de Sousa PA, Dvorak P, Freund C, Firpo M, Furue MK, Gokhale P, Ha HY, Han E, Haupt S, Healy L, Hei DJ, Hovatta O, Hunt C, Hwang SM, Inamdar MS, Isasi RM, Jaconi M, Jerike V, Kamthorn P, Kibbey MC, Knezevic I, Knowles BH, Koo SK, Laiby Y, Leopoldo I, Liu PA, Lomax GP, Longin JP, Ludwig JE, Montgomery K, Mummery C, Nagy A, Nakamura Y, Nakatsuji N, Oh S, Oh SK, Otonosoki T, Pera M, Peschanski M, Pranke P, Rajala KM, Rao M, Rattachuk R, Reubinoff B, Ricco L, Rooke H, Sipp D, Stacey GN, Suemori H, Takahashi TA, Takada K, Tális S, Tannenbaum S, Yuan BZ, Zeng F, Zhou Q. Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBII). Regen Med 2015; 10: 1-44 [PMID: 25875285 DOI: 10.2217/rme.14.93]

Akabayashi A, Nakazawa E, Jecker NS. Endangerment of the iPSC project in Japan: on the ethics of public funding policies. J Med Ethics 2018; 44: 700-702 [PMID: 30087154 DOI: 10.1136/medethics-2018-105024]
